The Canadian Co-infection Cohort is proud to be included in two international cohorts: InCHEHC and Hep-CAUSAL.
The Burnet Institute’s International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHECH) pools data from 15 observational cohorts from Australia, France, Spain, Switzerland, Netherlands, Georgia, United States, and Canada. It is the largest international cohort of people living with HIV with well-characterized data on HCV co-infection.
Pooling data from approximately 75,000 participants, the aim of this sizeable cohort is to measure and identify correlates of rare outcomes that cannot be analyzed within individual cohorts or countries, such as HCV reinfection after successful treatment, treatment failure, and liver-related mortality.
InCHEHC also allows for the interim assessment of the WHO elimination targets in 2020-2022, facilitating refinement of policy and practice within the target period.
Harvard’s School of Public Health’s Hep-CAUSAL is a consortium of cohorts of people who are co-infected with HIV and HCV in Europe and the Americas. By combining observational data and causal inference methods, Hep-CAUSAL estimates the long-term risk of HCV reinfection, hepatic disease, and extra-hepatic disease for all co-infected people. The findings are set to inform post-cure management guidelines and how to maximize the benefits of DAA treatment in the long term.
